Related Experiment Videos
Absence of TSG101 transcript abnormalities in human cancers
1Department of Otolarynogology-Head and Neck Surgery, The Johns Hopkins University, Baltimore, Maryland 21205-2196, USA.
Oncogene
|July 4, 1998
Summary
The TSG101 gene, initially suspected as a tumor suppressor, showed no consistent mutations or aberrant splicing in breast and Wilms' tumors. This suggests TSG101 is unlikely a primary target for inactivation in these human cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The human TSG101 gene is located on chromosome 11p15, a region implicated in various human cancers.
- Previous studies suggested TSG101 might function as a tumor suppressor gene, with reported abnormal transcripts and mutations in breast cancer.
Purpose of the Study:
- To investigate the role of the TSG101 gene in human cancers by analyzing its transcripts and coding sequence.
- To determine if TSG101 is a primary target for inactivation in breast cancer and Wilms' tumor.
Main Methods:
- Reverse transcription-PCR (RT-PCR) was used to amplify the open reading frame of TSG101 from various human tumor cell lines and primary tissues.
- Nested PCR was employed to further analyze transcript variants.
- Complete sequence analysis was performed to detect intragenic mutations in TSG101.
Main Results:
- RT-PCR detected expected TSG101 transcripts in most breast and Wilms' tumor samples.
- Nested PCR revealed aberrant bands in several cases, but their physiological relevance was questionable.
- No point mutations in the TSG101 gene were identified in any of the analyzed cancer samples, including those with chromosomal loss at 11p15.
Conclusions:
- The study found no consistent evidence of aberrant splicing or point mutations in TSG101 in breast cancer or Wilms' tumor.
- These findings suggest that TSG101 is not a primary target of inactivation in these human cancers.
- The role of TSG101 as a tumor suppressor gene in these specific cancers requires further investigation.